Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.

1
ZUSAMMENARBEIT Gesundheit und Forschung
zugunsten kleiner und mittlerer Unternehmen
(KMUs) im 7. EU-Rahmenprogramm Ylva
Huber Bereich Europäische und Internationale
Programme FFG Österreichische
Forschungsförderungsgesellschaft
2
Inhalt

• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu Gesundheit
• Forschung zugunsten kleiner und mittlerer
  Unternehmen (KMU)

3
Inhalt

• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu Gesundheit
• Forschung zugunsten kleiner und mittlerer
  Unternehmen (KMU)

4
(No Transcript)
5
Instrumente im 7. RP
7. EU-Rahmenprogramm 6. EU-Rahmenprogramm
Verbundprojekte (Collaborative Projects) Integrierte Projekte (IP) Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE) Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie) Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm Ideas)
KMU spezifische Maßnahmen KMU spezifische Maßnahmen
Artikel 169 Artikel 169
ERA-NET und ERA-NET PLUS ERA-NET
Gemeinsame Technologieinitiativen (JTI)
6
Die Ausschreibungen sind geöffnet!
rp7.ffg.at
7
Inhalt

• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu Gesundheit
• Forschung zugunsten kleiner und mittlerer
  Unternehmen (KMU)

8

• Ziele
• Verbesserung der Gesundheit der europäischen
  Bevölkerung
• Stärkung der europ. Industrie/Firmen im Bereich
  Gesundheit
• Blick auf globale Gesundheitsfragen
• (z.B. Epidemien
• Schwerpunkte
• Translationale Forschung (Grundlagenforschung ?
  klinische
  Anwendung)
• Neue Therapien (Entwicklung und Validierung)
• Methoden zur Gesundheitsförderung,
  Krankheitsprävention
• Diagnostische Instrumente und medizinische
  Technologien
• Effiziente Gesundheitssysteme

Thema 1- Gesundheit (6.050 Mio. Euro)
9
Thema 1 Gesundheit (6.050 Mio. )
Einreichfrist 1. Ausschreibung 19. April
2007 Einreichfrist 2. Ausschreibung 18.
September 2007

10

• High-throughput research
• Unifying human and model organism genetic
  variation databases
• Temporal and spatial proteomics to study
  biological processes relevant to human health
• Groundbreaking techniques for DNA sequencing and
  genotyping
• 2. Call
• SME-driven collaborative research projects for
  developing tools and technologies for
  high-throughput research
• Detection, Diagnosis and Monitoring
• Development of a hybrid imaging system
• Novel optical methodologies for detection,
  diagnosis and monitoring of disease or
  disease-related processes
• Novel targeted imaging probes for early in vivo
  diagnosis and/or evaluation of response to
  therapy
• In vivo image-guidance for cell therapy
• 2. Call
• Standardisation and improvement of pre-analytical
  procedures for in vitro diagnostics
• High throughput molecular diagnostics in
  individual patients for genetic diseases with
  heterogeneous clinical presentation

11

• Predicting suitability, safety and efficacy of
  therapies
• Thema zum Großteil durch Innovative Medicines
  Initiative (IMI) abgedeckt!
• Novel alternative testing strategies for use in
  pharmaceutical discovery and development
• Bottlenecks in reduction, refinement and
  replacement of animal testing in pharmaceutical
  discovery and development
• Promotion, development, validation, acceptance
  and implementation of QSARs (quantitative
  structure-activity relationship) for toxicology
• Alternative testing strategies for the assessment
  of the toxicological profile of nanoparticles
  used in medical diagnostics
• In silico modelling for ADMET outcomes

12

• Innovative therapeutic approaches and
  interventions
• Development and production of new generation
  antibodies
• Innovative approaches for the development of
  vaccines for young children
• Immunotherapy of human food allergies
• 2.Call
• Development of emerging gene therapy tools and
  technologies for clinical application
• Stem cell lines for cell-based therapies.
• Development of stem cell culture conditions.
• Stem cells for kidney regeneration.
• Adding value to EU stem cell therapy research
  scientific communication and future perspectives.

13

• Large-scale data gathering
• Networking biobanking initiatives across Europe
  developing standards and norms for existing and
  future human sample biobanks
• Molecular epidemiological studies in existing
  well characterised European (and/or other)
  population cohorts
• Comparative studies of genetic variation in
  humans towards a reference population in Europe
• Characterisation and variability of the microbial
  communities in the Human Body
• Structure-function analysis of membrane-transporte
  rs and channels for the identification of
  potential drug target sites
• High throughput analysis of lipids and
  lipid-protein interactions
• Genome-wide association studies in mammalian
  non-rodent models for the identification of genes
  relevant to human health and disease

14

• Systems biology
• A system approach to eukaryotic unicellular
  organism biology
• Modelling of T-cell activation
• Fundamental approaches to stem cell
  differentiation
• Developing an integrated in vitro, in vivo and
  systems biology modelling approach to
  understanding apoptosis in the context of health
  and disease
• 2. call
• Multidisciplinary fundamental genomics and
  molecular biology approaches to study basic
  biological processes relevant to health and
  diseases
• Coordination and Support Actions in large-scale
  data gathering and systems biology
• Traditional Chinese Medicine in post-genomic era.
  Specific International Cooperation Action.
  Targeted region China.

15

• Brain and related diseases
• Stroke and mechanisms underlying ischemic brain
  damage
• Coding in neuronal assemblies
• Neurobiology of anxiety disorders
• Memory loss underlying mechanisms and therapy
• From basic spinal mechanisms to spinal cord
  disease and trauma.
• Neuron-glia interactions in health and disease
• 2. Call
• Restorative approaches for therapy of
  neurodegenerative diseases.
• From mood disorders to experimental models.
• Neuronal mechanisms of vision and related
  diseases.
• Childhood and adolescent mental disorders.
  Specific International Cooperation Action. Target
  regions Eastern Europe and Central Asia and
  Western Balkans.

16

• Human Development and Ageing
• Novel approaches to reconstitute normal immune
  function at old age.
• Termination of developmental processes and their
  reactivation in adult life
• Biomarkers of ageing.
• Increasing the participation of elderly in
  clinical trials.
• Research on human development and/or healthy
  ageing across the EU

17

• Anti-microbial drug resistance including fungal
  pathogens
• 2. Call
• Novel targets for drugs against Gram negative
  bacteria.
• Host-pathogen interactions in infections by
  Streptococcus pneumoniae.
• An integrated platform for development and
  clinical evaluation of point-of-care diagnostic
  devices for microbial detection, antibiotic
  susceptibility determination and biomarkers
• Molecular epidemiology to control nosocomial and
  community spreading of highly virulent multi-drug
  resistant strains of bacterial pathogens.
• Health and economic cost of antimicrobial
  resistance.
• Conference on genetic and biochemical tools for
  postgenomic physiological analysis of
  Staphylococcus, in particular MRSA.

18

• HIV, AIDS, malaria and tuberculosis
• HIV/AIDS Drug Discovery and Preclinical
  Development
• Highly innovative approaches for research into
  host-pathogen interaction in tuberculosis
• Development of fast tests for the diagnosis of
  Multi-Drug-Resistant strains of HIV, malaria and
  tuberculosis and of latent tuberculosis infection
  (LTBI).
• Addressing knowledge gaps in pregnancy malaria.
• New HIV Vaccines inducing broadly-reactive
  neutralising antibodies.
• 2. Call
• Network on HIV and anti-HIV drug resistance
• HIV and Hepatitis co-infection
• Blocking the transmission of malaria the
  mosquito vector target.
• European network for study and clinical
  management of TB drug resistance.
• Support platform for the development of PRD
  vaccines
• Highly innovative research in HIV/AIDS, malaria
  and tuberculosis between Indian and European
  partners. (SICA, Targeted Region India)
• Coordination of European research activities with
  global initiatives, including Public-Private-Partn
  erships (SICA Targeted Regions ICPC).
• Next generation of researchers for HIV/AIDS,
  malaria, tuberculosis and neglected infectious
  diseases (SICA Targeted Regions ICPC).

19

• Potentially new and re-emerging epidemics
• Development of broadly protective influenza
  vaccine candidates.
• Identifying immunological mechanisms of
  protection for influenza vaccines
• Standardisation of immunological assays including
  surrogate markers for evaluation of new influenza
  vaccines in clinical trials
• Innovative point-of-care diagnostic tests for
  influenza.
• Development of additional treatment strategies
  for patients suffering from highly pathogenic
  influenza.
• Development of pandemic influenza containment and
  mitigation strategies.
• Supporting highly innovative inter-disciplinary
  research on influenza.
• Influenza research in collaboration with Asian
  partners. (SICA, Targeted regions Asia)
• 2. Call
• Strengthening research on prediction,
  identification, modelling and surveillance of
  newly emerging infectious diseases in humans.
• Definition of research needs and priorities in
  Europe in the area of Emerging Infectious
  Epidemics.

20

• Cancer
• Translating the knowledge on non-coding RNAs
  linked to the aetiology of cancer into novel
  diagnosis and therapy strategies.
• Translating clinical omics-technology
  (genomics, proteomics, metabolomics) into
  innovative cancer biomarkers aiding in early
  diagnosis, prognosis and treatment selection of
  cancer patients.
• Genomic instability and genomic alterations in
  pre-cancerous lesions and/or cancer.
• Novel cancer screening methods.
• Optimising research on end of life care of cancer
  patients.
• Understanding and fighting metastasis.
• Improving targeted drug delivery to cancer cells
  for cancer therapeutics other than gene therapy
• Developing high-throughput bioassays and models
  for human cancers in lower species.
• 2. Call
• Innovative combination clinical trials for
  multimodal cancer therapy.
• Role of inflammation in tumour initiation and
  progression.
• Epidemiology of gene-environment interactions
  involved in carcinogenesis.
• Translating the hypoxic tumour microenvironment.
• ERA-NET on optimisation of the use of cancer
  registries for cancer research purposes
• Studying cancer aetiology in Latin America. (SICA)

21

• Cardiovascular Disease
• Molecular basis of the inflammatory response and
  associated vascular remodelling in
  arteriosclerosis.
• Vascular remodelling in aneurysmal disease.
• Combating stroke.
• 2. Call
• Congenital pathologies affecting the heart.
• Cell therapies for the treatment of heart
  ischemia.
• Organ imaging in CVD.
• Integrating pharmacogenomic approaches into the
  treatment of CVD.

22

• Diabetes and Obesity
• Early processes in the pathogenesis of type 1
  diabetes and strategies for early prevention.
• Combined forms of diabetes in children.
• Insulin resistance as a key factor in the
  development of diabetes and metabolic syndrome.
• Pathophysiological mechanisms related to excess
  fat.
• A road-map for diabetes research.
• 2. Call
• Nutritional signals and the development of new
  diabetes/obesity therapeutic agents.
• Markers and treatment for diabetic neuropathy
  complications.
• Geno- and phenotypical differentiation of type 2
  subjects and monogenic subjects.
• Use of beta cell imaging in diabetes mellitus.

23

• Rare Diseases
• Natural course and pathophysiology of rare
  diseases.
• Research capacity-building in the field of rare
  diseases.
• Other Chronic Diseases
• Osteoarthritis.
• Inflammatory bowel disease.
• Osteoporosis signalling pathways in bone
  formation and homeostasis.
• Genetic factors of Osteoporosis.
• Intervertebral disc degeneration prevention and
  repair.
• Innovative concepts in chronic obstructive
  pulmonary disease pathogenesis (COPD).
• Hearing impairment and degeneration.
• Impairment of touch and proprioception at old
  age.
• Visual impairment and degeneration.
• 2. Call
• Understanding and combating age-related muscle
  weakness.
• Translational research aiming for a treatment of
  urinary incontinence.

24

• Translating clinical research into clinical
  practice including better use of
• medicines, and appropriate use of behavioural and
  organisational
• interventions and health therapies and
  technologies
• 2.call
• Implementation of research into healthcare
  practice
• Self-medication and patient safety
• Patient Safety Research Network
• Improving clinical decision making
• Better use of medicines.
• Continuity of clinical care.
• Patient self-management of chronic disease.
• Quality, solidarity and sustainability of health
  systems

25

• Enhanced health promotion and disease prevention
  
• 2.call
• Promoting healthy behaviour in children and
  adolescents
• Interventions addressing the gradient of health
  inequalities
• Public health interventions addressing the abuse
  of alcohol.
• Evaluation of suicide prevention strategies
  across and within European countries.
• Improve vaccination coverage
• Horizontal Coordination and Support Actions
  across Optimising the Delivery
• of Health Care to European Citizens
• 2.call
• Disease networks of centres of reference.

26

• Specific International Cooperation Actions for
  Health System Research
• 2.call
• Epidemiological investigations into long-term
  trends of population health as consequence of
  socio-economic transitions, including life-style
  induced health problems. SICA (Mediterranean
  Partner countries, Russia, Eastern European and
  Central Asia)
• Universal and equitable access to health care and
  health financing. SICA (MCP, ACP, Asia and Latin
  America)
• Health care intervention research optimising
  hospital care. SICA (Western Balkans.)
• Health care intervention research improving
  pre-natal and maternal care. SICA (ACP and
  Mediterranean Partner Countries)

27

• Coordination and Support Actions across the Theme
• Reinforcing the network of National Contact
  Points (NCP) for the Seventh Framework Programme
  under Health Theme by promoting transnational
  co-operation.)
• Promoting participation of high-technology
  research intensive SMEs, operating in the
  biomedical engineering and other medical
  technology sectorsrelevant to Health Theme.
• Assessment and valorisation of project outcome
  for hightechnology and research intensive SME
  participating to Framework Programmes of Research
  in the healthcare sector.
• Science communication actions.
• Initiatives to foster dialogue and debate on
  health research issues of interest to the public.
• Studies on the impact of EU legislation on health
  research and related developments and
  applications.
• 2.call
• Promotion and facilitation of international
  cooperation in areas relevant to the objectives
  of this theme. (SICA, ICPC)
• Responding to EU policy needs (2.call)
• Paediatric medicinal products, Drug safety
  research, Living and work conditions, Health
  statistics, Tobacco Control

28
Technologieplattformen und Gemeinsame
Technologieinitiativen

• Mobilisierung europäischer Ressourcen im Bereich
  Forschung, technologische Entwicklung und
  Innovation durch Zusammenbringen aller Akteure
  eines definierten Forschungsbereiches (Industrie,
  KMU, Universitäten, Endverbraucher)
• Industriegetrieben
• Gemeinsame Definition und Erstellung einer
  strategischen Forschungsagenda (mittel- bis
  langfristig)
• Input zur Entwicklung der thematischen
  Programme im 7. RP
• Einige wenige werden als Gemeinsame
  Technologieinitiativen (Joint Technology
  Initiatives) etabliert
• Neuer Weg zur Realisierung von public-private
  partnerships auf EU-Ebene mit definierter
  rechtlicher Struktur

29
Example Innovative Medicines - en route to a
Joint Technology Initiative

• Accelerated Development of safe and more
  effective medicines
• Revitalization of the the biopharmaceutical
  research and development (RD) environment for
  Europe to become more competitive
• Improving the collaboration between all relevant
  actors from public and private organisations
  (public-private partnerships)
• Draft and Implementation of a European Research
  Agenda
• Second version of the Strategic Research
  Agenda published recently
• First Calls expected for end of 2007/beginning
  of 2008
• http//europa.eu.int/comm/research/fp6/index_en.cf
  m?p1_innomed
• http//rp7.ffg.at/RP7.aspx_param_target_is_116120.
  v.aspx

30

•  Innovative Medicines 
• 2. version of the  Strategic Research Agenda 
• 4 main topics
• Safety
• Early safety evaluation and risk
  assessment, creation of a European Centre
  for Drug Safety
• Efficacy
• Predictive pharmacology, biomarker
  identification and validation, patient
  recruitment and risk assessment
• Knowledge Management
• New technologies to control and analyse
  enormous quantities of information in an
  integrative and predictive way
• Education and Training
• Bridge gaps in expertise required to
  strengthen the biopharmaceutical RD process,
  creation of a European Medicines Research Academy

31

• Technologieplattform
•  Innovative Medicines 
• Contact in Austria
• Univ. Prof. Dr. Hans Georg Eichler,
• Vice Rector of the Medical University in
  Vienna
• vr_forschung_at_meduniwien.ac.at

32
Relevante Themen der 1.Ausschreibungen aus
anderen Bereichen

• Food, Agriculture, Fisheries and Biotechnology
• e.g. Fork to farm Food (including seafood),
  health and well being
• Information and Communication Technologies
• Objective ICT-2007.5.3 Virtual Physiological
  Human
• Nanosciences, Nanotechnologies, Materials and new
  Production
• Technologies
• Creation of a critical and commented database on
  the health,
• safety and environmental impact of nanoparticles
• Substantial innovation in the European medical
  industry development of
• nanotechnology-based systems for in-vivo
  diagnosis and therapy (in
• Coordination with topic HEALTH-2007-2.4.1-7 and
  HEALTH-2007-1.2-3 in
• Theme 1 "Health")
• Environment Environment and Health
• Security Topic SEC-2007-1.3-05 Water
  distribution surveillance Critical
  Infrastructure
• Protection

33
Inhalt

• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu Gesundheit
• Forschung zugunsten kleiner und mittlerer
  Unternehmen (KMU)

34
Zusammenarbeit zwischen Industrie und
FE-Dienstleistern

• Forschung zugunsten von Kleinen und Mittleren
  Unternehmen (KMUs)
• Forschung zugunsten von KMU-Verbänden

35
Kennzeichen

• Themen Bottom up Ansatz (gesamtes Feld der
  Wissenschaft Technologie)
• KMUs/KMU-Verbände lagern Forschung
  technologische Entwicklung aus
• Flexibilität bezüglich der intellectual property
  rights

36
Aktivitäten

• Forschungs- und technologische Entwicklungsaktivit
  äten
• Demonstrationsaktivitäten
• Andere Aktivitäten (Trainings, dissemination
  activities)
• Management-Aktivitäten

37
Research for SMEs
Project participation scheme
RTD-performers
Industry
at least 3 SMEs from at least 3 countries (MS,
AS)
at least 2 universities research
centres industrial companies research performing
SMEs
38
Research for SME-Associations
Project participation scheme
Industry
RTD-performers
at least 2 universities research
centres industrial companies research performing
SMEs
at least 3 SME-Ass. from at least 3 countries
(MS, AS) or 1 European SME-Ass. at least 2 SMEs
39
Research for SMEs/SME-Associations
Research for SMEs Research for SME associations
Duration 1 - 2 years 2 - 3 years
Number of partners 5 - 10 10 -15
Total budget 0.5 1.5 Million 1.5 4 Million
Activities RD, demonstration, management, other activities RD, demonstration, management, other activities
Share of RD carried out by RTD performers
60 Source European Commission
40
Einreichfristen

• Research for SMEs FP7-SME-2007-1
• Einreichfrist
  4.September 200
• Research for SME Associations
  FP7-SME-2007-2
• 
  Einreichfrist 1. Juni 2007
• Kontakt Dr. Ines Haberl, ines.haberl_at_ffg.at
• http//rp7.ffg.at/RP7.aspx
• http//cordis.europa.eu/en/home.html

41
Wichtige Dokumente zur Vorbereitung

• Arbeitsprogramme Annexes
• Guide for Applicants
• Rules for Participation
• Model Grant Agreement
• Leitfaden/Formular für Anbahnungsfinanzierung
• rp7.ffg.at -gt Services der FFG

42
Kontaktieren Sie uns!Ihre Ansprechpartner für
Life Sciences in der FFG/Bereich Europäische und
InternationaleProgramme

• Mag. Birgit Steininger
• Leiterin des Referats für Biowissenschaften,
• Nationale Kontaktstelle für Lebensmittel,
  Landwirtschaft und Biotechnologie (DW 4101)
• birgit.steininger_at_ffg.at
• Dr. Ylva Huber
• Nationale Kontaktstelle für Gesundheit (DW 4102)
• ylva.huber_at_ffg.at
• Dr. Ines Haberl
• Nationale Kontaktstelle für KMUs (DW 4103)
• Ines.haberl_at_ffg.at
• e-mail vorname.nachname_at_ffg
  .at, Tel [phone]-Durchwahl

43
Vielen Dank für Ihre Aufmerksamkeit viel
Erfolg für Ihre Projekte im 7. Rahmenprogramm!